Glofitamab

Columvi · Bispecific antibody · CD20 / CD3

Mechanism

Bispecific CD20xCD3 T-cell engaging antibody. Bridges T cells to CD20-expressing tumor cells to induce killing.

Indication in MCL

Under investigation for MCL

Approval Status

FDAUnder investigation for MCLApproved for R/R DLBCL; MCL trials ongoing

Key Trials

NP30179

Key Researchers

Tycel Phillips

Associate Professor · City of Hope

Related Papers (5)

Glofitamab for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Apr 2025

Reply to: Glofitamab for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Apr 2025

Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jan 2025

A Case Report of Sustained Cytokine Release Syndrome Due to Glofitamab and Literature Review.

Clinical pharmacology : advances and applications · Jan 2025

Glofitamab-Associated Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Presenting as Serial Seizures and Responding Positively to Antiseizure Drugs and Anakinra: A Case Report.

Cureus · May 2024